Literature DB >> 33536566

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.

Jiandong Huo1,2,3, Audrey Le Bas2,3, Reinis R Ruza2, Helen M E Duyvesteyn2, Halina Mikolajek4, Tomas Malinauskas2, Tiong Kit Tan5, Pramila Rijal5,6, Maud Dumoux1, Philip N Ward2,3, Jingshan Ren2, Daming Zhou2, Peter J Harrison2,3, Miriam Weckener1, Daniel K Clare4, Vinod K Vogirala4, Julika Radecke4, Lucile Moynié1, Yuguang Zhao2, Javier Gilbert-Jaramillo7, Michael L Knight7, Julia A Tree8, Karen R Buttigieg8, Naomi Coombes8, Michael J Elmore8, Miles W Carroll8, Loic Carrique2, Pranav N M Shah2, William James7, Alain R Townsend5,6, David I Stuart2,4, Raymond J Owens9,10,11, James H Naismith12,13,14.   

Abstract

Entities:  

Year:  2021        PMID： 33536566      PMCID： PMC7857722          DOI： 10.1038/s41594-021-00566-w

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN： 1545-9985            Impact factor:   15.369


× No keyword cloud information.
Correction to: Nature Structural & Molecular Biology 10.1038/s41594-020-0469-6, published online 13 July 2020. In the version of this article initially published, author Jiandong Huo’s name was spelt incorrectly. The error has been corrected in the HTML and PDF versions of the article.
  1 in total

Review 1.  Research progress and applications of nanobody in human infectious diseases.

Authors:  Yaxian Mei; Yuanzhi Chen; Jwala P Sivaccumar; Zhiqiang An; Ningshao Xia; Wenxin Luo
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.